

悪性腫瘍に対する診断／治療薬剤の開発研究 -放射性銅標識薬剤による ラジオセラノスティクス-

薬学部 物理系薬学 藤澤 豊

$^{64/67}\text{Cu}$ -labeled compound X





Figure 1. (A) Structure of $^{64/67}\text{Cu}$ -labeled compound X. (B) Coronal (a), transverse (b) and sagittal (c) PET images at 40 hr after administration of ^{64}Cu -labeled compound X. (C, D) Effects of ^{67}Cu -labeled compound X on the growth of implanted AR42J tumors and the ratio of body weight, and mouse photographs with enucleated tumor at 14th day. Data represent mean $\pm$ SEM. Significant differences compared with the group of treatment with none (•) or ligand (†) were determined by 2-way ANOVA followed by Tukey test ($p < 0.05$).

Cu(II)-chelatable novel amino acid



ペプチド薬剤へ挿入した利用、LAT1を標的とした単体での利用など、
悪性腫瘍の新規診断／治療用薬剤への応用が期待される。